PubRank

Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. (ParvOryx01)

Clinical Trial ID NCT01301430

PubWeight™ 18.70‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01301430

Top papers

Rank Title Journal Year PubWeight™‹?›
1 New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 2013 1.72
2 Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013 1.36
3 Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J 2012 1.35
4 Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer 2012 1.35
5 Glioma virus therapies between bench and bedside. Neuro Oncol 2014 0.95
6 Sui generis: gene therapy and delivery systems for the treatment of glioblastoma. Neuro Oncol 2015 0.94
7 Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going? Viruses 2015 0.92
8 Strategies in gene therapy for glioblastoma. Cancers (Basel) 2013 0.87
9 Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Mol Ther Methods Clin Dev 2016 0.86
10 EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. Drugs Future 2016 0.84
11 Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data. Hum Gene Ther 2015 0.83
12 Gene therapy for malignant glioma. Mol Cell Ther 2014 0.83
13 Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology 2015 0.83
14 Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. Front Oncol 2014 0.82
15 Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells. J Virol 2014 0.79
16 Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats. Comp Med 2015 0.78
17 Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. Int J Cancer 2013 0.78
18 Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"? Mol Ther Oncolytics 2015 0.77
19 LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells. J Virol 2012 0.77
20 Pathology, organ distribution, and immune response after single and repeated intravenous injection of rats with clinical-grade parvovirus H1. Comp Med 2015 0.76
Next 100